Ignite Creation Date:
2024-05-06 @ 3:55 AM
Last Modification Date:
2024-10-26 @ 11:40 AM
Study NCT ID:
NCT02402764
Status:
COMPLETED
Last Update Posted:
2020-09-11
First Post:
2015-03-25
Brief Title:
Phase 2 Trial of Selinexor KPT-330 for Metastatic Triple Negative Breast Cancer TNBC
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
Investigator-Initiated Phase 2 Clinical Trial of Selinexor KPT-330 for the Treatment of Metastatic Triple Negative Breast Cancer
Status:
COMPLETED
Status Verified Date:
2020-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to see whether the combination of selinexor KPT-330 can help people with triple negative breast cancer TNBC Researchers also want to study the safety and tolerability of Selinexor in TNBC patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None